Sr. Director, Portfolio Strategy and Analytics | Onsite San Diego HQ

Who We Are:

Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life‑changing treatments for patients with under‑addressed neurological, psychiatric, endocrine and immunological disorders. The company’s diverse portfolio includes FDA‑approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader‑Willi syndrome, endometriosis
* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid‑ to late‑phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science.

(
* in collaboration with Abb Vie)

Responsible for leading and advancing enterprise portfolio strategy, optimization, analytics, and resource planning capabilities across Neurocrine’s research and development portfolio. Serves as a strategic advisor to executive leadership, providing data‑driven insights and recommendations that support portfolio prioritization, investment decisions, resource allocation, and long‑range planning. Leads highly complex portfolio planning and analytics activities with significant organizational impact, risk, and complexity. Develops and implements portfolio optimization frameworks, forecasting models, scenario analyses, and decision‑support capabilities that enable effective governance and maximize portfolio value.

Partners closely with R&D, Finance, Program Management, Business Development, and Executive Leadership to drive strategic decision‑making across discovery, development, and lifecycle programmes. Serves as the enterprise subject matter expert for portfolio planning systems, portfolio analytics, and resource optimisation methodologies while driving continuous improvement of portfolio management capabilities across the organization.

• Leads development and execution of enterprise portfolio strategy, prioritisation, and optimisation frameworks aligned with corporate and R&D objectives
• Owns and manages Neurocrine’s multi‑year compound flow model, including risk‑adjusted and non‑risk‑adjusted portfolio scenarios across therapeutic areas and development stages
• Develops and maintains transition probability models across development stages and modalities to support portfolio forecasting, investment planning, and strategic decision‑making
• Leads executive‑level portfolio prioritisation and trade‑off discussions, translating complex portfolio data into actionable recommendations that support portfolio investment and resource allocation decisions
• Evaluates portfolio opportunities, risks, development scenarios, and investment alternatives to maximise overall portfolio value
• Designs and oversees quantitative models supporting portfolio forecasting, probability of success analyses, development timelines, resource planning, and investment decision‑making
• Develops scenario analyses evaluating the impact of adding, removing, accelerating, delaying, or restructuring portfolio programmes
• Analyzes pipeline progression, development productivity, attrition rates, cycle times, and key portfolio performance indicators to support strategic planning and governance discussions
• Leads enterprise resource planning and capacity forecasting activities across functions, therapeutic areas, and development stages
• Partners with Finance, Program Management, and functional leaders to align portfolio objectives with organisational capacity, budgetary constraints, and long‑range planning assumptions
• Develops portfolio‑level financial models supporting annual operating plans, investment prioritisation, resource planning, and budget forecasting activities
• Identifies resource constraints, operational risks, and strategic…